We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

IN8BIO Inc (INAB) USD0.0001

Sell:$5.85 Buy:$7.00 Change: $0.0001 (0.00%)
Market closed |  Prices as at close on 15 October 2021 | Switch to live prices |
Change: $0.0001 (0.00%)
Market closed |  Prices as at close on 15 October 2021 | Switch to live prices |
Change: $0.0001 (0.00%)
Market closed |  Prices as at close on 15 October 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

IN8bio, Inc. is a clinical-stage biotechnology company. The Company is focused on and developing therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The Company's product candidate includes INB-200 and INB-100. INB-200 is genetically modified autologous gamma-delta T cell product candidate that the Company is developing for the treatment of solid tumors. Its indication for INB-200 is glioblastoma (GBM). INB-100 is its allogeneic product candidate that is developed for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation (HSCT). The Company is also developing a portfolio of preclinical programs. INB-400 is its preclinical program focused on developing allogeneic cellular therapies for solid tumor cancers and INB-300 is the preclinical program focused on developing product candidates based on gamma-delta T cells with an added chimeric antigen receptor (CAR).

Contact details

79 Madison Avenue, 2Nd Floor
United States
+1 (646) 6006438

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$112.53 million
Shares in issue:
18.75 million
United States
US dollar

Key personnel

  • Alan Roemer
  • William Ho
    President, Chief Executive Officer, Director
  • Lawrence Lamb
    Co-Founder, Executive Vice President, Chief Scientific Officer
  • Patrick Mccall
    Chief Financial Officer
  • Melissa Beelen
    Vice President - Clinical Operations
  • Kate Rochlin
    Vice President- Operations and Innovation

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.